ArticleMolecular medicine reports2018

CRISPR/Cas9 targeting of the androgen receptor suppresses the growth of LNCaP human prostate cancer cells.

Chaogang Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.